- Home
- RIVN vs BMRN Comparison
RIVN vs BMRN Comparison
Compare RIVN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- BMRN
- Stock Information
- Founded
- RIVN 2009
- BMRN 1996
- Country
- RIVN United States
- BMRN United States
- Employees
- RIVN N/A
- BMRN N/A
- Industry
- RIVN Auto Manufacturing
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RIVN Consumer Discretionary
- BMRN Health Care
- Exchange
- RIVN Nasdaq
- BMRN Nasdaq
- Market Cap
- RIVN 13.0B
- BMRN 13.7B
- IPO Year
- RIVN 2021
- BMRN 1999
- Fundamental
- Price
- RIVN $12.29
- BMRN $70.31
- Analyst Decision
- RIVN Hold
- BMRN Buy
- Analyst Count
- RIVN 21
- BMRN 22
- Target Price
- RIVN $14.10
- BMRN $94.00
- AVG Volume (30 Days)
- RIVN 28.7M
- BMRN 1.5M
- Earning Date
- RIVN 05-06-2025
- BMRN 04-23-2025
- Dividend Yield
- RIVN N/A
- BMRN N/A
- EPS Growth
- RIVN N/A
- BMRN 153.71
- EPS
- RIVN N/A
- BMRN 2.21
- Revenue
- RIVN $4,970,000,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- RIVN $10.80
- BMRN $12.23
- Revenue Next Year
- RIVN $36.10
- BMRN $9.90
- P/E Ratio
- RIVN N/A
- BMRN $32.37
- Revenue Growth
- RIVN 12.09
- BMRN 17.97
- 52 Week Low
- RIVN $8.26
- BMRN $60.63
- 52 Week High
- RIVN $18.86
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- RIVN 55.06
- BMRN 46.15
- Support Level
- RIVN $10.72
- BMRN $69.60
- Resistance Level
- RIVN $13.30
- BMRN $73.18
- Average True Range (ATR)
- RIVN 0.62
- BMRN 1.63
- MACD
- RIVN 0.25
- BMRN -0.32
- Stochastic Oscillator
- RIVN 68.44
- BMRN 19.75
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.